La cadena de opciones muestra datos clave de las opciones de acciones de Cyclacel Pharmaceuticals a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Cyclacel Pharmaceuticals..

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Bolsa, Cadena de Opciones

Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock

Cycclone Inc

<h3>Gainers</h3>
<ul>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock rose 29.1% to $8.9 during Tuesday's after-market session. The market value of their outstanding shares is at $34.1 million. </li>
<li>Repare Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) stock increased by 18.18% to $1.69. The market value of their outstanding shares is at $67.3 million. </li>
<li>Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) shares rose 8.84% to $10.58. The market value of their outstanding shares is at $54.2 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares rose 8.44% to $1.67. The market value of their outstanding shares is at $138.8 million. </li>
<li>Pheton Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTHL#NASDAQ">PTHL</a>) shares moved upwards by 6.74% to $22.0. The company's market cap stands at $312.0 million. </li>
<li>Scienture Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNX#NASDAQ">SCNX</a>) stock moved upwards by 6.43% to $1.82. The market value of their outstanding shares is at $21.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares declined by 23.8% to $9.4 during Tuesday's after-market session. The market value of their outstanding shares is at $5.2 million. </li>
<li>Gain Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) shares fell 14.71% to $1.45. The market value of their outstanding shares is at $54.9 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) shares fell 9.41% to $1.06. The company's market cap stands at $11.5 million. </li>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) stock decreased by 6.44% to $0.29. The market value of their outstanding shares is at $45.8 million. </li>
<li>Ikena Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKNA#NASDAQ">IKNA</a>) shares declined by 6.34% to $1.33. The company's market cap stands at $66.1 million. </li>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) shares declined by 6.06% to $2.33. The company's market cap stands at $53.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BDSX

CELU

CTOR

CYCC

GANX

IKNA

KAPA

NUWE

PTHL

RBOT

RPTX

SCNX

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares increased by 400.0% to $16.55 during Tuesday's regular session. The company's market cap stands at $5.2 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares moved upwards by 99.62% to $5.28. The market value of their outstanding shares is at $2.6 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) stock rose 65.66% to $1.14. The company's market cap stands at $11.5 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares rose 34.23% to $0.92. The company's market cap stands at $3.6 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) shares moved upwards by 20.0% to $3.96. The company's market cap stands at $9.2 million. </li>
<li>SS Innovations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>) stock increased by 18.16% to $5.61. The company's market cap stands at $919.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) shares fell 38.8% to $0.43 during Tuesday's regular session. The company's market cap stands at $27.4 million. </li>
<li>MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) shares decreased by 29.09% to $28.8. The company's market cap stands at $161.8 million. </li>
<li>Simulations Plus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) shares decreased by 24.79% to $13.14. The market value of their outstanding shares is at $351.3 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock decreased by 24.22% to $0.7. The market value of their outstanding shares is at $1.9 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) stock declined by 18.94% to $1.75. The company's market cap stands at $3.1 million. </li>
<li>Kyverna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYTX#NASDAQ">KYTX</a>) stock declined by 14.23% to $3.77. The company's market cap stands at $189.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INKT

KYTX

LIXT

PLRZ

RANI

SSII

SXTP

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Tuesday's Intraday Session

Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock is trading higher on Tuesday, with a session volume of 21.9 million compared to the average volume of 206.9K, <a href="https://www.benzinga.com/pro/feature/newsfeed" target="_blank" rel="noreferrer noopener">as per data from Benzinga Pro</a>.
Notably, there is no news to justify the stock movement.
<h2 class="wp-block-heading">Here&#8217;s what happened with the company recently:</h2>
Last week, Cyclacel entered into an amendment to the Exchange Agreement with FITTERS Diversified Berhad, an investment holding company engaged, through its subsidiaries, in the business of the sale of fire safety materials, equipment and fire prevention systems, &#8220;Waste-To-Resource&#8221; services and real estate <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46269846/cyclacel-pharmaceuticals-announces-amendment-to-exchange-agreement" rel="noreferrer noopener">development and construction</a>.
The company highlighted a publication from independent investigators published online in the journal Gut.
The study&#8217;s authors described in the publication reported that DNAJ-PKAc, a fusion oncoprotein known to drive FLC progression, makes the cancer sensitive to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46269854/cyclacel-pharmaceuticals-highlights-publication-of-preclinical-data-showing-that-plogosertib-is-ac" rel="noreferrer noopener">treatment with plogosertib</a>.
The researchers found that PLK1 is essential for FLC cells, making them highly sensitive to loss of PLK1.
A direct interaction was found between DNAJ-PKAc fusions in the centrosome and PLK1, thus promoting mitotic progression.
Pharmacologic inhibitors of PLK1, such as plogosertib, significantly reduced FLC growth but spared normal liver cells in patient-derived in vitro and in vivo xenograft models and an orthotopic model.
In July, Cyclacel implemented a second <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46218616/cyclacel-pharmaceuticals-announces-stock-split" rel="noreferrer noopener">reverse stock split</a>, 1-for-15, and in May, it announced a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45251639/cyclacel-pharmaceuticals-announces-stock-split" rel="noreferrer noopener">1-for-16 reverse stock split</a>.
In June, Cyclacel announced a private placement yielding gross proceeds of $3.0 million. The company issued series A, B and C warrants to purchase 3.27 million shares for each warrant at an exercise price of 51 cents per share, 60 cents per share and <a href="https://www.benzinga.com/pressreleases/25/06/g46038528/cyclacel-pharmaceuticals-announces-3-million-private-placement-offering-of-convertible-preferred-s" target="_blank" rel="noreferrer noopener">68 cents per share, respectively</a>.
CYCC Price Action: Cyclacel stock is up 318.43% at $13.85 at publication on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/07/46396470/elevance-steps-in-as-unitedhealth-delays-will-it-set-the-tone-for-insurers" target="_blank" rel="noreferrer noopener">Elevance Steps In As UnitedHealth Delays — Will It Set The Tone For Insurers?</a> Photo: Shutterstock</li>
</ul>

Biotech

News

Health Care

Trading Ideas

General

Why Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday?

Cyclacel Pharmaceuticals Shares Resume Then Halt Again On Circuit Breaker, Now Up 398.5%

Cyclacel Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 348.6%

Cyclacel Pharmaceuticals Shares Resume Trading

Cyclacel Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 239.6%

Cyclacel Pharmaceuticals Shares Resume Then Halt Again On Circuit Breaker, Now Up 114.2%

Cyclacel Pharmaceuticals Shares Resume Trade

Cyclacel Pharmaceuticals Shares Resume Then Halt Again On Circuit Breaker, Now Up 82.5%

Cyclacel Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 55.3%

<h3>Gainers</h3>
<ul>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) stock rose 127.6% to $6.02 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.6 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock moved upwards by 44.46% to $4.78. The market value of their outstanding shares is at $5.2 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) stock rose 40.11% to $0.96. The market value of their outstanding shares is at $11.5 million. </li>
<li>OKYO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKYO#NASDAQ">OKYO</a>) stock increased by 20.15% to $3.1. The market value of their outstanding shares is at $96.5 million. </li>
<li>Cadrenal Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVKD#NASDAQ">CVKD</a>) shares rose 19.43% to $14.93. The market value of their outstanding shares is at $24.5 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) shares rose 16.85% to $2.53. The company's market cap stands at $3.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Organogenesis Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGO#NASDAQ">ORGO</a>) stock declined by 24.3% to $3.4 during Tuesday's pre-market session. The company's market cap stands at $569.5 million. </li>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) shares declined by 18.05% to $7.9. The company's market cap stands at $30.5 million. </li>
<li>Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) stock decreased by 17.53% to $0.58. The market value of their outstanding shares is at $27.4 million. </li>
<li>Burning Rock Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNR#NASDAQ">BNR</a>) stock decreased by 17.5% to $3.82. The company's market cap stands at $47.4 million. </li>
<li>Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) shares decreased by 15.6% to $0.4. The market value of their outstanding shares is at $9.7 million. </li>
<li>MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) shares fell 13.82% to $35.0. The market value of their outstanding shares is at $161.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CVKD

OKYO

ORGO

SONN

TLPH

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Shares of The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) rose sharply in pre-market trading following the announcement <a href="https://www.benzinga.com/markets/equities/25/07/46407569/the-trade-desk-shares-spike-15-after-hours-heres-why-the-stock-is-trending-tonight">of its inclusion in the S&amp;P 500 index.</a>
This development comes after the S&amp;P Dow Jones Indices revealed that The Trade Desk would replace ANSYS Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANSS#NASDAQ">ANSS</a>) in the S&amp;P 500, effective from the market open on July 18.
Trade Desk shares jumped 14.8% to $86.60 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>SMX (Security Matters) Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>) climbed 122% to $3.73 in pre-market trading after dipping 27% on Monday.</li>
<li>Longevity Health Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) surged 101.5% to $5.33 in pre-market trading after the company announced a merger with THPlasma and the termination of its transaction with 20/20 BioLabs.</li>
<li>60 Degrees Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) jumped 89% to $4.09 in pre-market trading after falling 15% on Monday.</li>
<li>BloomZ Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) rose 63.9% to $0.2477 in pre-market trading after the company announced it is partnering with HYPERCOMMUNITY to deliver an AI-driven VTuber platform.</li>
<li>Brazil Potash Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRO#NYSE">GRO</a>) jumped 52.4% to $2.21 in pre-market trading after the company signed an MoU with Fictor &amp; WTT S.A., outlining terms for Fictor Energia to fund approximately $200 million in power transmission construction costs for the Autazes Project.</li>
<li>Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) gained 38.7% to $4.59 in pre-market trading after dipping over 10% on Monday.</li>
<li>Movano Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOVE#NASDAQ">MOVE</a>) gained 30% to $0.7135 in pre-market trading after dipping 21% on Monday.</li>
<li>Fusion Fuel Green PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTOO#NASDAQ">HTOO</a>) gained 20% to $4.71 in pre-market trading after dipping 30% on Monday.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) gained 18% to $14.99 in pre-market trading after gaining 10% on Monday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>LQR House Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YHC#NASDAQ">YHC</a>) declined 35% to $2.99 in pre-market trading. LQR House filed for common stock offering of $46 million.</li>
<li>S&amp;W Seed Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANW#NASDAQ">SANW</a>) dipped 33.6% to $1.60 in pre-market trading. S&amp;W announced voluntary delisting from Nasdaq and SEC deregistration.</li>
<li>TROOPS, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROO#NASDAQ">TROO</a>) dipped 29.9% to $0.94 in pre-market trading after gaining 105% on Monday.</li>
<li>Presidio Property Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SQFT#NASDAQ">SQFT</a>) shares tumbled 29.9% to $9.55 in pre-market trading after jumping 166% on Monday. The company announced the pricing of a $2.05 million registered direct offering of 170,830 shares at $12.00 per share.</li>
<li>MiNK Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) fell 27.5% to $29.45 in pre-market trading after dipping 37% on Monday. William Blair analyst Matt Phipps, on Monday, downgraded MiNK Therapeutics from Outperform to Market Perform.</li>
<li>Organogenesis Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGO#NASDAQ">ORGO</a>) fell 26.7% to $3.29 in pre-market trading after gaining over 4% on Monday.</li>
<li>MiMedx Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXG#NASDAQ">MDXG</a>) declined 20.7% to $5.38 in pre-market trading.</li>
<li>Australian Oilseeds Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOT#NASDAQ">COOT</a>) fell 15% to $0.4405 in pre-market trading after gaining over 5% on Monday.</li>
<li>Sequans Communications S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQNS#NYSE">SQNS</a>) fell 10.8% to $5.01 in pre-market trading. Sequans shares gained around 20% on Monday after the company announced it bought 683 more Bitcoins and provided updates on its total holdings.</li>
<li>Simulations Plus, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) shares fell 6.3% to $16.37 in pre-market trading after the company reported downbeat third-quarter sales and cut its FY2025 EPS guidance.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46408189/jpmorgan-wells-fargo-and-3-stocks-to-watch-heading-into-tuesday">JPMorgan, Wells Fargo And 3 Stocks To Watch Heading Into Tuesday</a></li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

ANSS

BLMZ

COOT

HTOO

MDXG

MOVE

SANW

SQFT

SQNS

TROO

Why Trade Desk Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket

WIIM

Cyclacel Pharmaceuticals shares are trading lower after the company announced it will acquire Fitters Sdn. Bhd. from FITTERS Diversified.

Cyclacel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>, "Cyclacel" or the "Company"))), a biopharmaceutical company developing innovative medicines, today announced that it has entered into an amendment to the Exchange Agreement with FITTERS Diversified Berhad (9318.KL; "FITTERS"), an investment holding company engaged, through its subsidiaries, in the business of the sale of fire safety materials, equipment and fire prevention systems, "Waste-To-Resource" services and real estate development and construction.
Pursuant to the Exchange Agreement, all of the ordinary shares of FITTERS' subsidiary, Fitters Sdn. Bhd., a Malaysia-based private limited company ("Fitters Sub") shall be exchanged for common stock, par value $0.001, of Cyclacel (the "Purchaser Stock"), and Fitters Sub shall be continuing as a wholly-owned subsidiary of Cyclacel (the "Transaction"). As part of the Transaction, Cyclacel shall issue an amount of Purchaser Stock equal to 19.99% percent, which percentage may be subject to adjustment, of the issued and outstanding shares of Purchaser Stock as of the closing date to FITTERS. The amendment provides that in addition to the Purchaser Stock, Cyclacel will pay USD $1,000,000 or a mutually agreed upon amount at closing, to FITTERS as consideration under the Exchange Agreement. Additionally, the parties agreed to extend the Final Date (as defined under the Exchange Agreement) to September 30, 2025.
The Transaction is subject to approval from Cyclacel stockholders and FITTERS. The Exchange Agreement has been unanimously approved by the Boards of Directors of each of Cyclacel, FITTERS and Fitters Sub.

CYCCP

Reported Earlier: Cyclacel Pharmaceuticals To Acquire Fitters Sdn. Bhd. From FITTERS Diversified Via Share Exchange Representing 19.99% Of Cyclacel Stock Plus $1M Cash Payment

Cyclacel Highlights Study Showing Plogosertib Targets DNAJ-PKAc Fusion In Rare Liver Cancer Fibrolamellar Hepatocellular Carcinoma

<h3>Gainers</h3>
<ul>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock moved upwards by 82.6% to $2.21 during Wednesday's regular session. The market value of their outstanding shares is at $3.8 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) stock moved upwards by 49.15% to $1.76. The market value of their outstanding shares is at $3.2 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares moved upwards by 40.9% to $14.88. The market value of their outstanding shares is at $53.9 million. </li>
<li>NeOnc Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTHI#NASDAQ">NTHI</a>) stock increased by 31.34% to $4.4. The company's market cap stands at $63.7 million. </li>
<li>Nutriband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) shares moved upwards by 27.93% to $10.26. The market value of their outstanding shares is at $89.2 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares moved upwards by 25.39% to $0.69. The company's market cap stands at $2.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) shares decreased by 39.6% to $34.19 during Wednesday's regular session. The market value of their outstanding shares is at $28.1 billion. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) stock decreased by 38.44% to $1.26. The company's market cap stands at $8.9 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares decreased by 27.37% to $10.61. The company's market cap stands at $7.2 billion. As per the news, the H1 earnings report came out 2 days ago. </li>
<li>CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) stock declined by 25.82% to $0.96. The market value of their outstanding shares is at $80.7 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock declined by 20.43% to $0.27. The market value of their outstanding shares is at $7.9 million. </li>
<li>Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) shares declined by 20.18% to $244.5. The market value of their outstanding shares is at $16.6 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTSO

EYEN

MBIO

NTHI

NTRB

WINT

12 Health Care Stocks Moving In Wednesday's Intraday Session

Cyclacel Pharmaceuticals share are trading lower after the company announced a 1-for-15 reverse stock split.

Stock Split

Cyclacel Pharmaceuticals Announces 1-for-15 Reverse Stock Split, Effective Jul. 7

Cyclacel Pharmaceuticals Reveals $3M Private Placement Offering Of Convertible Preferred Stock

Press Releases

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock

Earnings

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN. BHD. ITS WHOLLY-OWNED SUBSIDIARY TO ACCELERATE GROWTH AND STOCKHOLDER VALUE

CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT

CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

Financing

Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock

Cyclacel Pharmaceuticals Announces Stock Split

CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER

Comments

Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals (CYCC) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL